DIABETES

1. Most overweight and obese patients with Type 1 diabetes can consider using OPTIFAST® VLCD™.

2. Due to the risk of hypoglycaemia, it is imperative that blood glucose levels are monitored more frequently for the first few days (at least 4 times per day – once before each meal and before going to bed).

3. The aim is to prevent hypoglycaemia from occurring. Therefore, it is imperative that you work with your patient to get the insulin dosage right.

4. It is extremely important that insulin treatment is continued, no matter how low the insulin dose is. Do not completely cease insulin treatment.

1. Most obese patients with Type 2 diabetes can consider using OPTIFAST® VLCD™ as part of an overall weight management program.

2. If your patient is not on any insulin or taking Metformin, thiazolidenediones or acarbose, then they should benefit, like non-diabetic patients from the hunger-suppressing effects of mild ketosis.

3. Hypoglycaemia is a risk for patients on insulin or sulphonylureas therefore it is imperative that blood glucose levels are monitored more frequently for the first few days (at least 4 times per day – once before each meal and before going to bed).

4. The aim is to prevent hypoglycaemic episodes from occurring therefore it is imperative that you work with your patient to get their medication dosage right.